Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study
- 226 Downloads
Non-muscle invasive bladder cancer (BC) is a highly recurrent disease, with the first recurrences arising shortly after transurethral resection of the bladder (TURB). Topical administration of interleukin-2 (IL-2) has been shown as an effective adjuvant therapy for BC; however, predictive biomarkers that may identify suitable subgroups of patients are lacking. In this pilot study we sought to determine the prognostic value of epigenetic and genetic inactivation of tumour suppressor genes (TSGs) among BC patients treated with IL-2.
After complete TURB, patients with multifocal superficial BC were treated with five daily intravesical instillations of IL-2. Promoter hypermethylation in six TSGs and the TP53 gene mutations were prospectively assessed by methylation-specific PCR and automated capillary single-strand conformation polymorphism in 21 primary bladder cancer specimens and ten bladder wall biopsies collected during follow-up.
After IL-2 treatment, 9 out of 21 (43%) patients did not develop recurrent tumour within the 1 year of follow-up period. The mean duration of recurrence-free survival in the rest of the study group was 112 days. In the current pilot study, BC with p16 gene hypermethylation had a lower risk of recurrence after treatment with IL-2, as compared to IL-2 treated BC without p16 hypermethylation (p = 0.02). Significant associations were observed between tumour grade and the mean methylation index (p = 0.003), as well as the hypermethylation of the RARβ gene (p = 0.048).
Our preliminary data suggest that DNA methylation biomarkers may assist in selection of BC patients for efficient IL-2 therapy.
KeywordsBladder cancer Promoter hypermethylation Interleukin-2 Tumour suppressor genes p16 gene
This work was supported by grants B-17/2005 and C-03/2007 from the Lithuanian State Science and Studies Foundation, and COST grant BM0703. We thank Dr. D. Characiejus for organizing IL-2 treatment at the Oncology Institute of Vilnius University and for valuable comments on the manuscript.
Conflict of interest statement
We declare that we have no conflict of interest.
- Bubeník J (2004) Interleukin-2 therapy of cancer. Folia Biol (Praha) 50(3–4):120–130Google Scholar
- Holmila R, Husgafvel-Pursiainen K (2006) Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing. Cancer Detect Prev 30(1):1–6CrossRefPubMedGoogle Scholar
- IUAC (2002) IUAC TNM classification of malignant tumors, 6th edn. John Wiley and Sons, New YorkGoogle Scholar
- Josephson DY, Pasin E, Stein JP (2006) Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther 6(12):1723−1734Google Scholar
- Kirkali Z, Chan T, Manoharan M et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl 1):4−34Google Scholar
- Mostofi FK, Sobin LH, Torlini H (1973) Histological typing of urinary bladder tumors. In: International histological classification of tumors, No 10. World Health Organization, GenevaGoogle Scholar